Multidomain Efficacy and Safety of Guselkumab Through 1 Year in Patients With Active Psoriatic Arthritis With and Without Prior Tumor Necrosis Factor Inhibitor Experience: Analysis of the Phase 3, Randomized, Placebo‐Controlled DISCOVER‐1 Study

OBJECTIVE: To evaluate efficacy and safety of the interleukin‐23p19‐subunit inhibitor, guselkumab, in DISCOVER‐1 patients with active psoriatic arthritis (PsA) by prior use of tumor necrosis factor inhibitor (TNFi). METHODS: The phase 3, randomized, placebo‐controlled DISCOVER‐1 study enrolled patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Ritchlin, Christopher T., Deodhar, Atul, Boehncke, Wolf‐Henning, Soriano, Enrique R., Kollmeier, Alexa P., Xu, Xie L., Zazzetti, Federico, Shawi, May, Jiang, Yusang, Sheng, Shihong, Helliwell, Philip S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Wiley Periodicals, Inc. 2023
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010489/
https://www.ncbi.nlm.nih.gov/pubmed/36762512
http://dx.doi.org/10.1002/acr2.11523

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10010489/
https://www.ncbi.nlm.nih.gov/pubmed/36762512
http://dx.doi.org/10.1002/acr2.11523

Ejemplares similares